<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-ZHLLDCO3/342badf0-7610-4e91-95f0-cead84069b38/PDF"><dcterms:extent>866 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-ZHLLDCO3/589bf1ca-ed79-4a2a-b23c-fa1e76f9cfa9/TEXT"><dcterms:extent>22 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2022-2025"><edm:begin xml:lang="en">2022</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-ZHLLDCO3"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-UCB4A42Q" /><dcterms:issued>2025</dcterms:issued><dc:creator>Bizjak, Ela</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">str. 37-40</dc:format><dc:identifier>COBISSID_HOST:248504067</dc:identifier><dc:identifier>ISSN:2820-5014</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-ZHLLDCO3</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Fakulteta za farmacijo, ŠSSFD</dc:publisher><dcterms:isPartOf xml:lang="sl">Placebo</dcterms:isPartOf><dc:subject xml:lang="en">adipose derived mesenchymal stem cells</dc:subject><dc:subject xml:lang="en">atopic dermatitis</dc:subject><dc:subject xml:lang="sl">atopijski dermatitis</dc:subject><dc:subject xml:lang="sl">celice T-pomagalke tipa 2</dc:subject><dc:subject xml:lang="sl">Dermatitis</dc:subject><dc:subject xml:lang="en">filaggrin</dc:subject><dc:subject xml:lang="sl">filagrin</dc:subject><dc:subject xml:lang="sl">kožna bariera</dc:subject><dc:subject xml:lang="sl">Mezenhimske matične celice</dc:subject><dc:subject xml:lang="sl">mezenhimske matične celice maščobnega izvora</dc:subject><dc:subject xml:lang="en">microbiome</dc:subject><dc:subject xml:lang="sl">mikrobiom</dc:subject><dc:subject xml:lang="en">skin barrier</dc:subject><dc:subject xml:lang="en">T helper 2 cells</dc:subject><dcterms:temporal rdf:resource="2022-2025" /><dc:title xml:lang="sl">Potencial uporabe mezenhimskih matičnih celic maščobnega izvora za zdravljenje atopijskega dermatitisa| splošno o dermatoveneroloških boleznih|</dc:title><dc:description xml:lang="sl">Atopic dermatitis (AD) is a complex, chronic infl ammatory skin disease characterized by itching, infl ammation, and dryness of the skin. The causes of the disease are multifactorial and not fully understood. They involve dysfunction of the immune system, damage to the skin barrier, genetic predispositions, and changes in the skin microbiome. Various types of T cells (Th1, Th2, Th17, Th22), mast cells, and eosinophils participate in the immune response, releasing infl ammatory cytokines that cause acute and chronic infl ammation. Genetic mutations, particularly in the gene for fi laggrin, further weaken the skin barrier. Microbiome alterations, especially colonization of the skin by Staphylococcus aureus, further worsen the condition. Traditional treatment is based on corticosteroids and immunomodulators, but these have numerous side eff ects and are prone to resistance development. Recent studies have identifi ed adipose-derived mesenchymal stem cells (AD-MSCs) as a promising therapy, as their low immunogenicity and strong immunomodulatory and regenerative properties help suppress infl ammation and repair damaged skin. Moreover, their isolation is less invasive compared to other types of mesenchymal cells</dc:description><dc:description xml:lang="sl">Atopijski dermatitis (AD) je kompleksna, kronična vnetna bolezen kože, ki se izraža s srbečico, vnetjem in suhostjo kože. Vzrokov za pojav bolezni je več in niso popolnoma razjasnjeni. Vključuje motnje v delovanju imunskega sistema, poškodbe kožne bariere, genetske predispozicije in spremembe v kožnem mikrobiomu. V imunskem odzivu sodelujejo različni tipi celic T (Th1, Th2, Th17, Th22), mastociti in eozinofi lci, ki s sproščanjem vnetnih citokinov povzročajo akutno in kronično vnetje. Genetske mutacije, predvsem v genu za fi lagrin, dodatno oslabijo kožno bariero. Mikrobiomske spremembe, predvsem kolonizacija kože s Staphylococcus aureus, še poslabšajo stanje. Klasično zdravljenje temelji na kortikosteroidih in imunomodulatorjih, vendar prinaša številne neželene učinke in pogosto vodi v razvoj odpornosti. V novejših raziskavah se kot obetavna terapija pojavljajo mezenhimske matične celice maščobnega izvora (ADMSC), ki zaradi svoje nizke imunogenosti ter izrazitih imunomodulatornih in regenerativnih lastnosti zavirajo vnetje in obnavljajo poškodovano kožo, njihova izolacija pa je v primerjavi z ostalimi tipi mezenhimskih celic najmanj invazivna</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-ZHLLDCO3"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-ZHLLDCO3" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-ZHLLDCO3/342badf0-7610-4e91-95f0-cead84069b38/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:dataProvider xml:lang="en">National and University Library of Slovenia</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-ZHLLDCO3/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-ZHLLDCO3" /></ore:Aggregation></rdf:RDF>